DHL strengthens health logistics with acquisition
DHL will acquire 100% of CRYOPDP, a specialty courier providing logistics services for clinical trials, biopharma, and cell and gene therapies from Cryoport, Inc.
THE ACQUISITION enhances DHL’s capabilities in specialty pharma logistics and supports Group’s 2030 strategy to become a leader in life science and healthcare logistics.
The companies also announced a strategic partnership to strengthen their supply chain service offerings for the global life sciences and healthcare sector.
DHL Group has an established Life Sciences and Healthcare business, contributing over EUR 5 billion in global revenue in 2024.
The acquisition aligns with DHL Group’s Strategy 2030, which emphasizes the importance of temperature-controlled networks, first and last mile specialty courier coverage and integrated solutions.
For Cryoport, the partnership with DHL will enable it to better execute its business in EMEA and APAC.
The deal and the outlined partnership are subject to regulatory approvals.
